Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
AstraZeneca said on February 17 that it will kick off a registry study to evaluate the efficacy and safety of Imfinzi (durvalumab) following curative chemoradiotherapy in patients with limited-stage small cell lung cancer (SCLC) in Japan. The study, named TSUBAKI,…
To read the full story
BUSINESS
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
- Pfizer’s Tukysa Makes Japan Debut for HER2-Positive Breast Cancer
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…